Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efimosfermin Alfa in Hepatic Impairment Due to Steatotic Liver Disease
NCT07358546Phase 1Recruiting
- Sponsor
- GSK
- Start
- Mar 2026
- Primary completion
- Oct 2027
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of efimosfermin in metabolic dysfunction-associated steatohepatitis (MASH) (3 arms), sponsored by GSK. Primary endpoints: Area under the serum drug concentration versus time curve from time zero to infinity up to 90 Days and Maximum observed serum drug concentration up to 90 Days. Started Mar 2026; status: recruiting.
02
Drugs
efimosfermin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT07358546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07358546.